Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Laboratory/Clinical Translational Research

Coexpression of Gas6/Axl in Human Ovarian Cancers

Sun W. · Fujimoto J. · Tamaya T.

Author affiliations

Departmentof Obstetrics and Gynecology, Gifu University School of Medicine, Gifu City, Japan

Related Articles for ""

Oncology 2004;66:450–457

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Laboratory/Clinical Translational Research

Received: July 14, 2003
Accepted: November 21, 2003
Published online: September 24, 2004
Issue release date: September 2004

Number of Print Pages: 8
Number of Figures: 6
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

Objectives: Gas6, the protein product of the growth arrest-specific gene 6 (gas6), a member of the vitamin K-dependent protein family, was identified as a ligand for the Axl/Sky family of receptor tyrosine kinases. The aim is to study for the presence of Gas6 and its receptor Axl and Sky related to specific growth in the ovarian cancers, and to evaluate their plausible growth potential and mechanism. Methods: In ovarian cancers of 90 cases, the histoscores and mRNA levels of Gas6, Axl and Sky were determined by immunohistochemistry and competitive reverse transcription-polymerase chain reaction-Southern blot analysis using the recombinant RNA, respectively. Results: The histoscores and mRNA levels of Gas6 and Axl in ovarian cancers were significantly higher than in normal ovaries, regardless of histopathological type or clinical stage of ovarian cancers. Conclusions: Gas6/Axl pathway could play a role in the complex events taking place during the early changes of ovarian cancer progression.

© 2004 S. Karger AG, Basel


References

  1. Manfioletti G, Brancolini C, Avanzi G, Schneider C: The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 1993;13:4976–4985.
  2. Lundwall A, Dackowski W, Cohen E, Shaffer M, Mahr A, Dahlback B, Stenflo J, Wydro R: Isolation and sequence of the cDNA for human protein S, a regulator of blood coagulation. Proc Natl Acad Sci USA 1986;83:6716–6720.
  3. Godowski PJ, Mark MR, Chen J, Sadick MD, Raab H, Hammonds RG: Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3. Cell 1995;82:355–358.
  4. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, Hunt RW, Trail G, Clogston C, Toso RJ, et al: Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995;373:623–626.
  5. Chen J, Carey K, Godowski PJ: Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene 1997;14:2033–2039.
  6. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, Mizuno K: Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996;271:30022–30027.
  7. Crosier KE, Crosier PS: New insights into the control of cell growth; the role of the Axl family. Pathology 1997;29:131–135.
  8. Nakano T, Higashino K, Kikuchi N, Kishino J, Nomura K, Fujita H, Ohara O, Arita H: Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca(2+)-mobilizing growth factors. J Biol Chem 1995;270:5702–5705.
  9. Nakano T, Kawamoto K, Kishino J, Nomura K, Higashino K, Arita H: Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: Contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem J 1997;323:387–392.
  10. McCloskey P, Fridell YW, Attar E, Villa J, Jin Y, Varnum B, Liu ET: GAS6 mediates adhesion of cells expressing the receptor tyrosine kinases Axl. J Biol Chem 1997;272:23285–23291.
  11. Goruppi S, Ruaro E, Schneider C: Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 1996;12:471–480.
  12. Nakano T, Kawamoto K, Higashino K, Arita H: Prevention of growth arrest-induced cell death of vascular smooth muscle cells by a product of growth arrest-specific gene gas6. FEBS Lett 1996;387:78–80.
  13. Goruppi S, Chiaruttini C, Ruaro ME, Varnum B, Schneider C: Gas6 induces growth, beta-catenin stabilization, and T-cell factor transcription activation in contact-inhibited C57 mammary cells. Mol Cell Biol 2001;21:902–915.
  14. Prieto AL, Weber JL, Tracy S, Heeb MJ, Lai C: Gas6, a ligand for the receptor protein-tyrosine kinase Tyro-3, is widely expressed in the central nervous system. Brain Res 1999;816:646–661.
  15. Chan MCW, Mather JP, Mccray G, Lee WM: Identification and regulation of receptor tyrosine kinases Rse and Mer and their ligand Gas6 in testicular somatic cells. J Andrology 2000;21:291–302.
  16. Healy AM, Schwartz JJ, Zhu X, Herrick BE, Varnum B, Farber HW: Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells. Am J Physiol 2001;280:L1273–L1281.
  17. Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M: A receptor tyrosine expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 2001;37:2264–2274.
  18. Sun WS, Misao R, Iwagaki S, Fujimoto J, Tamaya T: Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine endometrium and ovarian endometriosis. Mol Hum Reprod 2002;8:552–558.
  19. Sun WS, Fujimoto J, Tamaya T: Coexpression of growth arrest specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine endometrial cancers. Ann Oncol 2003;14:898–906.
  20. Faust M, Ebensperger C, Schulz AS, Schleithoff L, Hameister H, Bartram CR, Janssen JW: The murine ufo receptor: Molecular cloning, chromosomal localization and in situ expression. Oncogene 1992;7:1287–1293.
  21. Neubauer A, Fiebeler A, Graham DK, O’Bryan JP, Schmidt CA, Barckow P, Serke S, Siegert W, Snodgrass HR, Huhn D, et al: Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 1994;84:1931–1941.
  22. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS: Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ 1994;5:647–657.
  23. Berclaz G, Altermatt HJ, Rohrbach V, Kieffer I, Dreffer E, Andres AC: Estrogen dependent expression of the receptor tyrosine kinases axl in normal and malignant human breast. Ann Oncol 2001;12:819–824.
  24. Quong RY, Bickford ST, Ing YL, Terman B, Herlyn M, Lassam NJ: Protein kinases in normal and transformed melanocytes. Melanoma Res 1994;4:313–319.
  25. Fujimoto J, Yamamoto T: brt, a mouse gene encoding a novel receptor-type protein-tyrosine kinase, is preferentially expressed in the brain. Oncogene 1994;9:693–698.
  26. Lai C, Gore M, Lemke G: Structure, expression, and activity of Tyro 3, a neural adhesion-related tyrosine kinase. Oncogene 1994;9:2567–2578.
  27. Ohashi K, Honda S, Ichinomiya N, Nakamura T, Mizuno K: Molecular cloning and situ localization in the brain of rat sky receptor tyrosine kinase. J Biochem 1995;117:1267–1275.
  28. Yamagita M, Arai H, Ishii K, Nakano T, Ohashi K, Mizuno K, Varnum B, Fukatsu A, Doi T, Kita T: Gas6 regulated mesangial cell proliferation though Axl in experimental glomerulonephritis. Am J Pathol 2001;158:1423–1432.
  29. The FIGO committee: FIGO, News. Int J Gynecol Obstet 1989;28:189–193.
  30. Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, Ambros PF, Bartram CR: A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 1991;6:2113–2120.
  31. Vanden Heuvel JP, Tyson FL, Bell DA: Construction of recombinant RNA templates for use as internal standards in quantitative RT-PCR. Biotechniques 1993;14:395–398.
  32. Ohashi K, Mizuno K, Kuma K, Miyata T, Nakamura T: Cloning of the cDNA for a novel receptor tyrosine kinase, Sky, predominantly expressed in brain. Oncogene 1994;9:699–705.
  33. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
  34. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577–580.
  35. Shi SR, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741–748.
  36. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KSSr: Estrogen receptor analysis, correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716–721.
  37. Li R, Chen J, Hammonds G, Philips H, Armanini M, Wood P, Bunge R, Godowsky PJ, Sliwkowski MX, Mather JP: Identification of Gas6 as a growth factor for human Schwann cell. J Neurosci 1996;16:2012–2019.
  38. Bellosta P, Costa M, Lin DA, Basiloco C: The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol 1995;15:614–625.
  39. Fridell Y-WC, Jin Y, Quilliam LA, Burchert A, McCloskey P, Spizz G, Varnum B, Der C, Liu ET: Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the axl receptor tyrosine kinase Axl. Mol Cell Biol 1996;16:135–145.
  40. Craven RJ, Xu L, Weiner TM, Fridell YW, Dent GA, Srivastava S, Varnum B, Liu ET, Cance WG: Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 1995;60:791–797.
  41. Allen MP, Zeng C, Schneider K, Xiong X, Meintzer MK, Bellosta P, Basilico C, Varnum B, Heigenreich KA, Wierman ME: Growth arrest-specific gene 6 (Gas6)/Adhesion related kinase (Ark) signaling promotes gonadotropin-releasing hormone neuronal survival via extracellular signal-regulated kinase (ERK) and Akt. Mol Endocrinol 1999;13:191–201.
  42. Tanaka K, Nagayama Y, Nakano T, Takamura N, Namba H, Fukada S, Kuma K, Yamashita S, Niwa M: Expression profile of receptor-type protein tyrosine kinase gene in the human thyroid. Endocrinology 1998;139:852–858.
  43. Ito M, Nakashima M, Nakayama T, Ohtsuru A, Nagayama Y, Takamura N, Demedchik EP, Sekine I, Yamashita S: Expression of receptor-type tyrosine, Axl and its ligand, Gas6, in pediatric thyroid carcinomas around Chernobyl. Thyroid 2002;12:971–975.

Article / Publication Details

First-Page Preview
Abstract of Laboratory/Clinical Translational Research

Received: July 14, 2003
Accepted: November 21, 2003
Published online: September 24, 2004
Issue release date: September 2004

Number of Print Pages: 8
Number of Figures: 6
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.